GILEAD SCIENCES, INC.

GILD 10-Q · Q2 2025
API behind this page

GILD Q2 2025 request

Playground key active
Request URL /api/financials?ticker=GILD&year=2025&quarter=2
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q2 2025 Q2 2024 YoY
Revenue 7,082 6,954 +1.8%
Show Product Lines breakouts
AmBisome 129 151 -14.6%
AmBisome · Europe 65 69 -5.8%
AmBisome · Rest of World 56 65 -13.8%
AmBisome · US 7 17 -58.8%
Biktarvy 3,530 3,232 +9.2%
Biktarvy · Europe 429 370 +15.9%
Biktarvy · Rest of World 302 277 +9.0%
Biktarvy · US 2,799 2,585 +8.3%
Descovy 653 485 +34.6%
Descovy · Europe 24 25 -4.0%
Descovy · Rest of World 28 26 +7.7%
Descovy · US 601 434 +38.5%
Genvoya 377 440 -14.3%
Genvoya · Europe 40 45 -11.1%
Genvoya · Rest of World 16 23 -30.4%
Genvoya · US 322 372 -13.4%
Odefsey 298 315 -5.4%
Odefsey · Europe 66 72 -8.3%
Odefsey · Rest of World 11 10 +10.0%
Odefsey · US 221 233 -5.2%
Other 73 130 -43.8%
Other HIV 107 105 +1.9%
Other HIV · Europe 33 25 +32.0%
Other HIV · Rest of World 9 15 -40.0%
Other HIV · US 65 65 0.0%
Other Liver Disease 201 113 +77.9%
Other Liver Disease · Europe 76 47 +61.7%
Other Liver Disease · Rest of World 19 19 0.0%
Other Liver Disease · US 106 47 +125.5%
Other · Europe 8 8 0.0%
Other · Rest of World 21 24 -12.5%
Other · US 44 98 -55.1%
Product 7,054 6,912 +2.1%
Product · Europe 1,178 1,118 +5.4%
Product · Rest of World 838 878 -4.6%
Product · US 5,038 4,916 +2.5%
Royalty, contract and other revenues 27 41 -34.1%
Royalty, contract and other revenues · Europe 10 15 -33.3%
Royalty, contract and other revenues · Rest of World 4 1 +300.0%
Royalty, contract and other revenues · US 13 25 -48.0%
Sofosbuvir/Velpatasvir 342 476 -28.2%
Sofosbuvir/Velpatasvir · Europe 81 84 -3.6%
Sofosbuvir/Velpatasvir · Rest of World 76 126 -39.7%
Sofosbuvir/Velpatasvir · US 184 267 -31.1%
Symtuza - Revenue share 124 168 -26.2%
Symtuza - Revenue share · Europe 33 34 -2.9%
Symtuza - Revenue share · Rest of World 3 3 0.0%
Symtuza - Revenue share · US 88 131 -32.8%
Tecartus 92 107 -14.0%
Tecartus · Europe 41 37 +10.8%
Tecartus · Rest of World 9 7 +28.6%
Tecartus · US 41 63 -34.9%
Total Cell Therapy 485 521 -6.9%
Total Cell Therapy · Europe 196 206 -4.9%
Total Cell Therapy · Rest of World 86 66 +30.3%
Total Cell Therapy · US 203 250 -18.8%
Total HIV 5,088 4,745 +7.2%
Total HIV · Europe 624 571 +9.3%
Total HIV · Rest of World 368 353 +4.2%
Total HIV · US 4,096 3,821 +7.2%
Total Liver Disease 795 832 -4.4%
Total Liver Disease · Europe 170 142 +19.7%
Total Liver Disease · Rest of World 211 259 -18.5%
Total Liver Disease · US 413 431 -4.2%
Total Oncology 849 841 +1.0%
Total Oncology · Europe 291 275 +5.8%
Total Oncology · Rest of World 131 92 +42.4%
Total Oncology · US 427 474 -9.9%
Total Other 202 280 -27.9%
Total Other · Europe 73 77 -5.2%
Total Other · Rest of World 77 88 -12.5%
Total Other · US 52 115 -54.8%
Trodelvy 364 320 +13.8%
Trodelvy · Europe 96 69 +39.1%
Trodelvy · Rest of World 44 26 +69.2%
Trodelvy · US 224 224 0.0%
Veklury 121 214 -43.5%
Veklury · Europe 19 53 -64.2%
Veklury · Rest of World 50 85 -41.2%
Veklury · US 51 76 -32.9%
Vemlidy 252 243 +3.7%
Vemlidy · Europe 13 11 +18.2%
Vemlidy · Rest of World 117 115 +1.7%
Vemlidy · US 122 117 +4.3%
Yescarta 393 414 -5.1%
Yescarta · Europe 154 169 -8.9%
Yescarta · Rest of World 77 58 +32.8%
Yescarta · US 162 186 -12.9%
Show Geography breakouts
Europe 1,189 1,133 +4.9%
Rest of World 842 879 -4.2%
US 5,051 4,941 +2.2%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income 19 5 +280.0%
Cost of Revenue 1,501 1,544 -2.8%
Research And Development Expense Excluding Acquired In Process Cost 1,491 1,351 +10.4%
Research And Development Asset Acquired Other Than Through Business Combination Written Off 61 38 +60.5%
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill 190 — —
Show Indefinite Lived Intangible Assets By Major Class breakouts
In Process Research And Development Bulevirtide 190 — —
Selling, General & Administrative 1,365 1,377 -0.9%
Show Business Segments breakouts
Reportable Segment 1,365 1,377 -0.9%
Total Costs & Expenses 4,608 4,309 +6.9%
Operating Income 2,474 2,644 -6.4%
Interest Expense 254 237 +7.2%
Non-Operating Income (Expense) -208 355 -158.6%
Income Before Taxes 2,429 2,053 +18.3%
Income Tax Expense (Benefit) 468 438 +6.8%
Show Equity Components breakouts
Income tax expense · Reclassification Out Of Accumulated Other Comprehensive Income 2 1 +100.0%
Net Income 1,960 1,614 +21.4%
Show Equity Components breakouts
Retained Earnings 1,960 1,614 +21.4%
Net Income 1,960 1,614 +21.4%
EPS (Basic) 1.57 1.29 +21.7%
EPS (Diluted) 1.56 1.29 +20.9%
Wtd Avg Shares (Basic) 1,245 1,247 -0.2%
Wtd Avg Shares (Diluted) 1,255 1,251 +0.3%
Sales & Marketing (Q) — — —
Show Business Segments breakouts
Reportable Segment 864 805 +7.3%
General & Administrative (Q) — — —
Show Business Segments breakouts
Reportable Segment 501 572 -12.4%
Other Non-Operating Income (Expense) 6 -1 +700.0%
Comprehensive Income 1,850 1,639 +12.9%
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax -166 23 -821.7%

Balance Sheet

Balance Sheet
Metric Q2 2025 Q2 2024 YoY
Current Assets
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5,144 2,772 +85.6%
Marketable Securities (Current) 69 — —
Accounts Receivable 4,781 4,663 +2.5%
Inventory 1,825 2,026 -9.9%
Prepaid Expenses & Other Current Assets 2,899 2,856 +1.5%
Total Current Assets 14,718 12,317 +19.5%
Non-Current Assets
Property, Plant & Equipment 5,459 — —
Marketable Securities (Non-Current) 1,913 — —
Goodwill 8,314 8,314 0.0%
Deferred Tax Assets 2,721 — —
Other Non-Current Assets 4,031 4,770 -15.5%
Total Assets 55,721 53,579 +4.0%
Intangible Assets 15,866 — —
Show Finite Lived Intangible Assets By Major Class breakouts
Hepcludex [Member] 473 — —
Intangible asset – axicabtagene ciloleucel 4,186 — —
Intangible asset – sofosbuvir 2,622 — —
Other Intangible Assets 479 — —
Trodelvy 8,107 — —
Other Assets
Intangible Assets Net Excluding Goodwill 18,566 — —
Current Liabilities
Accounts Payable 582 537 +8.4%
Accrued Rebates 4,215 3,923 +7.4%
Debt Current 2,806 1,810 +55.0%
Other Liabilities Current 3,586 — —
Total Current Liabilities 11,189 10,781 +3.8%
Current Portion of Long-Term Debt 2,806 — —
Non-Current Liabilities
Long-Term Debt 22,140 — —
Accrued Income Taxes Noncurrent 859 738 +16.4%
Deferred Tax Liabilities 652 907 -28.1%
Other Non-Current Liabilities 1,290 1,418 -9.0%
Long-Term Debt 24,946 — —
Show Debt Instrument breakouts
1.20% Senior Unsecured Notes Due October 2027 · Senior Notes 748 — —
1.65% Senior Unsecured Notes Due October 2030 · Senior Notes 996 — —
2.60% Senior Unsecured Notes Due October 2040 · Senior Notes 989 — —
2.80% Senior Unsecured Notes Due October 2050 · Senior Notes 1,479 — —
2.95% Senior Unsecured Notes Due March 2027 · Senior Notes 1,249 — —
3.65% Senior Unsecured Notes Due March 2026 · Senior Notes 2,748 — —
4.00% Senior Unsecured Notes Due September 2036 · Senior Notes 744 — —
4.15% Senior Unsecured Notes Due March 2047 · Senior Notes 1,730 — —
4.50% Senior Unsecured Notes Due February 2045 · Senior Notes 1,735 — —
4.60% Senior Unsecured Notes Due September 2035 · Senior Notes 994 — —
4.75% Senior Unsecured Notes Due March 2046 · Senior Notes 2,224 — —
4.80% Senior Unsecured Notes Due April 2044 · Senior Notes 1,738 — —
4.80% Senior Unsecured Notes Due In November 2029 · Senior Notes 747 — —
5.10% Senior Unsecured Notes Due June 2035 · Senior Notes 991 — —
5.25% Senior Unsecured Notes Due October 2033 · Senior Notes 993 — —
5.50% Senior Unsecured Notes Due November 2054 · Senior Notes 989 — —
5.55% Senior Unsecured Notes Due October 2053 · Senior Notes 988 — —
5.60% Senior Unsecured Notes Due November 2064 · Senior Notes 739 — —
5.65% Senior Unsecured Notes Due December 2041 · Senior Notes 997 — —
Show Long-Term Debt Type breakouts
Notes Payable Other Payables 1,127 — —
Stockholders' Equity
Common Stock 1 1 0.0%
Additional Paid-In Capital 8,367 7,022 +19.2%
Accumulated Other Comprehensive Income -18 93 -119.4%
Retained Earnings 11,325 11,165 +1.4%
Total Stockholders' Equity 19,674 18,281 +7.6%
Minority Interest -84 -84 0.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 19,590 18,197 +7.7%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent -127 47 -370.2%
Accumulated Net Unrealized Investment Gain Loss 4 — —
Accumulated Other Comprehensive Income -18 93 -119.4%
Accumulated Translation Adjustment 105 46 +128.3%
Additional Paid In Capital 8,367 7,022 +19.2%
Common Stock 1 1 0.0%
Noncontrolling Interest -84 -84 0.0%
Retained Earnings 11,325 11,165 +1.4%
Total Liabilities & Equity 55,721 53,579 +4.0%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q2 2025 YTD Q2 2024 YoY
Operating Activities
Depreciation 190 192 -1.0%
Adjustment For Amortization 1,197 1,192 +0.4%
Stock-Based Compensation 434 397 +9.3%
Deferred Income Taxes -377 -889 +57.6%
Increase Decrease In Equity Securities Fv Ni 284 405 -29.9%
Other Non-Cash Items 124 208 -40.4%
Change in Accounts Receivable -213 -95 -124.2%
Change in Inventory -398 -115 -246.1%
Change in Prepaid & Other Assets 93 -56 +266.1%
Change in Accounts Payable -267 -11 -2327.3%
Increase Decrease In Income Taxes -1,852 -1,379 -34.3%
Increase Decrease In Accrued Liabilities -410 -349 -17.5%
Net Cash from Operations 2,584 3,544 -27.1%
Investing Activities
Purchases of Investments -2,287 -244 -837.3%
Proceeds From Sale Of Available For Sale Securities Debt 295 2,265 -87.0%
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 15 327 -95.4%
Payments To Acquire Businesses Net Of Cash Acquired -294 -4,195 +93.0%
Payments To Acquire Other Investments -37 -444 +91.7%
Capital Expenditures -211 -235 +10.2%
Other Investing Activities -13 12 -208.3%
Net Cash from Investing -2,531 -2,514 -0.7%
Financing Activities
Proceeds From Issuance Of Common Stock 279 151 +84.8%
Share Repurchases -1,257 -500 -151.4%
Debt Repayments -1,771 -1,851 +4.3%
Payments Of Dividends -2,004 -1,962 -2.1%
Proceeds From Payments For Other Financing Activities -240 -152 -57.9%
Net Cash from Financing -4,993 -4,314 -15.7%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 92 -29 +417.2%
Net Change in Cash -4,848 -3,313 -46.3%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key